3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Endocrine
1
CNS
1
Conditions
Carcinoma, Renal Cell
13
Parkinson Disease 4, Autosomal Dominant Lewy Body
4
von Hippel-Lindau Disease
3
Pheochromocytoma
1
Paraganglioma
1
Kidney Neoplasms
1
Carcinoma
1
Breast Neoplasms
1
Adenoma, Islet Cell
1
Interventions
Specimen Handling
4
Magnetic Resonance Spectroscopy
4
Sunitinib
2
Everolimus
2
sargramostim
1
montanide ISA 51
1
lutetium Lu 177 dotatate
1
lanreotide
1
incomplete Freund's adjuvant
1
fludarabine phosphate
1
cabozantinib
1
belzutifan
1
atezolizumab
1
X-Rays
1
Temozolomide
1
Phantoms, Imaging
1
Octreotide
1
Methods
1
LY2940680
1
Interleukin-13
1
Immunoglobulin G
1
Fluorodeoxyglucose F18
1
Disulfides
1
Cyclophosphamide
1
Colony-Stimulating Factors
1
Blood Specimen Collection
1
Biopsy
1
Bevacizumab
1
11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo(5,4-a)pyrrolo(3,4-c)carbazol-4-one
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenoma, Islet Cell
×
belzutifan
×
90 days
×
Clear all
NCT04924075
2026-05-28
MK-6482-015
Merck Sharp & Dohme LLC
Phase 2
Recruiting
322 enrolled
1 FDA